Avantor (NYSE:AVTR) Given New $23.00 Price Target at Barclays

Avantor (NYSE:AVTR) had its target price lowered by analysts at Barclays from $26.00 to $23.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s target price indicates a potential upside of 20.10% from the stock’s current price.

AVTR has been the topic of a number of other reports. Robert W. Baird cut their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. UBS Group reiterated a “neutral” rating and set a $25.00 price target (down from $29.00) on shares of Avantor in a report on Friday, January 17th. Wells Fargo & Company dropped their price target on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, October 28th. Finally, Raymond James decreased their price target on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $27.08.

Avantor Stock Down 11.8 %

Shares of NYSE AVTR opened at $19.15 on Monday. The company has a market cap of $13.03 billion, a price-to-earnings ratio of 41.63, a PEG ratio of 3.87 and a beta of 1.28. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. Avantor has a 12 month low of $19.08 and a 12 month high of $28.00. The stock has a 50-day moving average price of $21.73 and a two-hundred day moving average price of $23.46.

Avantor (NYSE:AVTR) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same quarter in the previous year, the business posted $0.22 earnings per share. As a group, analysts forecast that Avantor will post 0.98 earnings per share for the current fiscal year.

Institutional Trading of Avantor

A number of institutional investors have recently modified their holdings of the business. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Avantor by 34.8% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 717,729 shares of the company’s stock valued at $15,123,000 after acquiring an additional 185,364 shares during the period. Wilson Asset Management International PTY Ltd. raised its stake in shares of Avantor by 6.4% during the 4th quarter. Wilson Asset Management International PTY Ltd. now owns 805,658 shares of the company’s stock valued at $16,975,000 after purchasing an additional 48,626 shares during the period. HighTower Advisors LLC raised its stake in shares of Avantor by 58.4% during the 4th quarter. HighTower Advisors LLC now owns 33,141 shares of the company’s stock valued at $698,000 after purchasing an additional 12,221 shares during the period. King Luther Capital Management Corp lifted its holdings in Avantor by 100.0% during the 4th quarter. King Luther Capital Management Corp now owns 16,000 shares of the company’s stock worth $337,000 after purchasing an additional 8,000 shares in the last quarter. Finally, Daiwa Securities Group Inc. boosted its stake in Avantor by 1.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 77,428 shares of the company’s stock worth $1,632,000 after purchasing an additional 1,346 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.